Press Releases

Press Releases

International Vaccine Institute and Technical University of Denmark to strengthen external quality assurance in the face of rising antimicrobial resistance in Asia

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


International Vaccine Institute joins the JEE Alliance

2017-12-05 05:15

The International Vaccine Institute (IVI) joined the JEE Alliance (Alliance for Country Assessments for Global Health Security and IHR Implementation) on November 14, 2017.

The JEE Alliance is a multi-sectoral platform for international cooperation to promote political, financial and technical support for implementation of the International Health Regulations (2005), which was launched in Geneva, Switzerland in May 2016. The alliance brings together like-minded players from relevant sectors in countries, organizations and other stakeholders involved in health security. As of November 2017, the alliance had 65 members including governments, international organizations, financial institutions, NGOs and a group of private sector organizations.

“IVI’s experience in and commitment to health security is a valuable contribution to the JEE Alliance. We look forward to IVI’s active participation in the JEE Alliance initiatives” co-chairs Ambassador Blair Exell and Dr Päivi Sillanaukee of the Alliance said in a letter to IVI.

Dr. Jerome Kim, Director General of IVI, said, “As an organization concerned with the development of vaccines for global health security, we are pleased to join the JEE Alliance and have a chance to promote vaccine R&D and vaccination as a critical component of global health security, and partner with other parties to contribute to health security.”

New member of the GHSA

IVI joined the JEE Alliance soon after becoming a member of the Global Health Security Agenda (GHSA), the action-oriented initiative aimed at advancing a world safe and secure from infectious disease threats in September 2017. In an effort to increase its contributions to global health, IVI expressed its desire to join the GHSA since participating as a technical advisor in the GHSA Steering Group (SG) meeting in Seoul, Korea in July.

“IVI has significant capability to collaborate with countries and organizations worldwide in accelerating the development and delivery of new vaccines for global health, and we have worked in more than 30 countries to study disease burden, and plan, support and conduct vaccine projects,” Dr. Jerome Kim said. “We are committed to the GHSA’s objectives to prevent, detect and promptly respond to infectious disease threats in collaboration with partners in order to ensure global health security.”

About International Health Regulations (2005):

The IHR are an international legal instrument that is binding on 196 countries across the globe, including all the Member States of the World Health Organization. Their aim is to help the international community prevent and respond to acute public health risks that have the potential to cross borders and threaten people worldwide. The IHR, which entered into force on 15 June 2007, require countries to report certain disease outbreaks and public health events to WHO.

About the GHSA

The Global Health Security Agenda (GHSA) was launched in February 2014 to enhance security from infectious disease threats, to bring together nations worldwide to make new, concrete commitments, and to promote global health security as a national leaders’ priority. The initiative has 50 nations, international organizations and NGOs as members, with the G7 having endorsed the GHSA in June 2014.